维布妥昔单抗治疗CD30阳性淋巴瘤
Brentuximab Vedotin in CD30+ Lymphomas.
作者信息
Perini Guilherme Fleury, Pro Barbara
机构信息
Hospital Israelita Albert Einstein, Sao Paulo, SP Brazil.
Fox Chase Cancer Center, Lymphoma Service, Philadelphia, PA USA.
出版信息
Biol Ther. 2013;3(1):15-23. doi: 10.1007/s13554-013-0008-7. Epub 2013 Mar 1.
Abstract
Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.
摘要
单克隆抗体（mAb）已成为血液系统恶性肿瘤的一种有效治疗策略。CD30是一种合理的治疗靶点，因为它在正常组织上表达有限，而在经典霍奇金淋巴瘤（cHL）和间变性大细胞淋巴瘤（ALCL）的恶性细胞上表达强烈且一致。抗CD30抗体药物偶联物brentuximab vedotin利用单克隆抗体的靶向特性将细胞毒性药物递送至恶性细胞内。Brentuximab vedotin在复发或难治性cHL以及复发或难治性ALCL患者中具有显著的临床活性，并且有可能代表现代肿瘤学的一项重大进展。
相似文献
1
Brentuximab Vedotin in CD30+ Lymphomas.
Biol Ther. 2013;3(1):15-23. doi: 10.1007/s13554-013-0008-7. Epub 2013 Mar 1.
2
Brentuximab vedotin in Hodgkin's lymphoma.
Expert Opin Biol Ther. 2012 Oct;12(10):1415-21. doi: 10.1517/14712598.2012.718328. Epub 2012 Aug 31.
3
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.
4
Brentuximab vedotin in systemic T-cell lymphoma.
Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.
5
Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Front Immunol. 2023 May 18;14:1203471. doi: 10.3389/fimmu.2023.1203471. eCollection 2023.
6
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Virchows Arch. 2024 Mar;484(3):465-473. doi: 10.1007/s00428-024-03764-1. Epub 2024 Feb 13.
7
Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin.
Clin Med Insights Oncol. 2012;6:31-9. doi: 10.4137/CMO.S6637. Epub 2012 Jan 4.
8
Brentuximab vedotin for the treatment of CD30+ lymphomas.
Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15.
9
Brentuximab vedotin in anaplastic large cell lymphoma.
Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.
10
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
引用本文的文献
1
Antibody-drug conjugates: Recent advances in linker chemistry.
Acta Pharm Sin B. 2021 Dec;11(12):3889-3907. doi: 10.1016/j.apsb.2021.03.042. Epub 2021 Apr 6.
2
Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases.
World Allergy Organ J. 2016 Feb 11;9:7. doi: 10.1186/s40413-016-0094-3. eCollection 2016.
3
[Clinicopathological features and prognositic analysis of Epstein-Barr virus- positive diffuse large B-cell lymphoma in elderly: 7 cases report and literatures review].
Zhonghua Xue Ye Xue Za Zhi. 2015 Aug;36(8):698-701. doi: 10.3760/cma.j.issn.0253-2727.2015.08.016.
4
Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
Drugs. 2015 Sep;75(14):1601-11. doi: 10.1007/s40265-015-0453-3.
5
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
Free Radic Biol Med. 2015 Jul;84:22-29. doi: 10.1016/j.freeradbiomed.2015.02.027. Epub 2015 Mar 19.
6
Principles in the design of ligand-targeted cancer therapeutics and imaging agents.
Nat Rev Drug Discov. 2015 Mar;14(3):203-19. doi: 10.1038/nrd4519. Epub 2015 Feb 20.
7
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0028. doi: 10.5041/RMMJ.10162. eCollection 2014 Oct.
本文引用的文献
1
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
2
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
J Clin Oncol. 2012 Jun 20;30(18):2197-203. doi: 10.1200/JCO.2011.38.1350. Epub 2012 Apr 30.
3
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17.
4
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
5
Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.
Leuk Lymphoma. 2012 Nov;53(11):2283-6. doi: 10.3109/10428194.2012.676170. Epub 2012 Apr 23.
6
Optimal therapy of advanced Hodgkin lymphoma.
Hematology Am Soc Hematol Educ Program. 2011;2011:310-6. doi: 10.1182/asheducation-2011.1.310.
7
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Clin Cancer Res. 2012 Jan 1;18(1):248-55. doi: 10.1158/1078-0432.CCR-11-1425. Epub 2011 Nov 11.
8
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21.
9
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18.
10
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.
Zotero 插件